Diabetes medications and cardiovascular outcome trials: Lessons learned

Article Figures & Data

TABLE 1

Novel diabetes drugs: Findings of cardiovascular outcome studies

Drug	Findings
Dipeptidyl peptidase-4 inhibitors
Alogliptin	Cardiovascular safety Heart failure caution
Linagliptin^a	Results not available
Saxagliptin	Cardiovascular safety Heart failure caution
Sitagliptin	Cardiovascular safety
Glucagon-like peptide-1 receptor agonists
Albiglutide^a	Results not available
Dulaglutide^a	Results not available
Exenatide^a	Results not available
Liraglutide^b	Cardiovascular benefit
Lixisenatide	Cardiovascular safety
Semaglutide^{^b,^c}	Cardiovascular benefit
Sodium-glucose cotransporter-2 inhibitors
Canagliflozin^a	Cardiovascular benefit Amputation caution
Dapagliflozin^a	Results not available
Empagliflozin	Cardiovascular benefit Cardiovascular death benefit
Ertugliflozin^a	Results not available

↵a Cardiovascular outcomes trials ongoing.
↵b Cardiovascular effects currently under review by the US Food and Drug Administration.
↵c Not available in United States.